Contact
Please use this form to send email to PR contact of this press release:
Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint
TO:
Please use this form to send email to PR contact of this press release:
Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint
TO: